Acute Myeloid Leukemia Coverage From Every Angle
Advertisement
Advertisement

Stéphane de Botton, MD, PhD, on AML: The Effect of Olutasidenib on Complete Remissions

Posted: Wednesday, July 14, 2021

St├ęphane de Botton, MD, PhD, of Gustave Roussy, discusses results from an interim analysis of a phase II clinical trial of olutasidenib, a small-molecule inhibitor of mutant IDH1, in patients with acute myeloid leukemia. The drug was reported to be well tolerated and induced durable complete response in a subset of patients with high-risk disease.



By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.